RPH Pharmaceuticals, a subsidiary of Recipharm AB, has filed an application for an undisclosed infectious disease drug product in a range of European countries. The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which will to market the product in the Nordic market.   The product, owned by RPH Pharmaceuticals, is a “first-in-class generic” and will be licensed to third parties for distribution in markets where Astimex presentl...